Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease

Indian Journal of Clinical Biochemistry

Volumn 26, Issue 2, 2011, Pages 202-209

  Das, Subir Kumar ^a   Balakrishnan, V ^b  

^a WBUHS   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Insulin resistance; Interleukin 6; Non alcoholic fatty liver disease; Transforming growth factor beta; Tumor necrosis factor alpha

Indexed keywords

EID: 84878831361     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-011-0121-7     Document Type: Article

References (55)

1. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000. (Pubitemid 43112663)
2. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8. (Pubitemid 10057164)
3. Das SK, Balakrishnan V, Mukherjee S, Vasudevan DM. Evaluation of blood oxidative stress related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2008;68(4):323-34. (Pubitemid 351962413)
4. Das SK, Mukherjee S, Vasudevan DM. Non-alcoholic fatty liver diseases: an under recognized cause with emerging importance. Current Sci. 2006;90:659-65.
5. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43:508-14. (Pubitemid 41111434)
6. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 2005;54(2):303-6. (Pubitemid 40139250)
7. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-52. (Pubitemid 39071617)
8. Day CP, James OF. Steatohepatitis - a tale of two hits. Gastroenterology. 1998;114:842-5.
9. McClain CJ, Mokshagundam SP, Barve SS, et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004;34:67-79. (Pubitemid 40163990)
10. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology. 2008;48(3):770-81.
11. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass - prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology. 1982;82:535-48. (Pubitemid 12166814)
12. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res. 2006;30:720-30.
13. Cameron RG, Neuman MG. Novel morphologic findings in alcoholic liver disease. Clin Biochem. 1999;32(7):579-84. (Pubitemid 30007769)
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9. (Pubitemid 15018832)
15. World Health Organization. Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999. Report No. WHO/NCD/NCS/99.2.
16. Das SK, Mukherjee S, Pandey G, Balakrishnan V, Vasudevan DM. Clinicopathological spectrum of non-alcoholic fatty liver disease among patients in Kerala. Indian J Clin Biochem. 2009;24(2):155-8.
17. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. (Pubitemid 46631552)
18. Ko GT, Wu MM, Tang J, Wai HP, Chan CH, Chen R. Body mass index profile in Hong Kong Chinese adults. Ann Acad Med Singapore. 2001;21(1):17-26.
19. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21(1):17-26. (Pubitemid 32240483)
20. Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and nonalcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009;25(2):150-5.
21. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Non alcoholic fatty liver, Steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-23. (Pubitemid 36397405)
22. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis. 2007;27:44-54.
23. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41:372-9. (Pubitemid 40165382)
24. Madan K, Batra Y, Gupta SD, Chander B, Rajan KD, Tewatia MS, et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol. 2006;12:3400-5.
25. Lee S, Jin Kim Y, Yong Jeon T, Hoi Kim H, Woo Oh S, Park Y, Soo Kim S. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scand J Gastroenterol. 2006;41(5):566-72.
26. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of non alcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5. (Pubitemid 29528333)
27. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-9. (Pubitemid 34106377)
28. Muoio DM, Negward CB. Molecular and metabolic mechanisms of insulin resistance and b-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:193-205. (Pubitemid 351301824)
29. Verges B. Insulin sensitiviy and lipids. Diabetes Metab. 2001;27(2 Pt 2):223-7.
30. Kojima H, Sakurai S, Uemura M, Takekawa T, Morimoto H, Tamagawa Y, Fukui H. Difference and similarity between nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res. 2005;29(Suppl 12):259S-63S. (Pubitemid 43053680)
31. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-23. (Pubitemid 30346988)
32. Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001;35:568-74. (Pubitemid 33078265)
33. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145-71.
34. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289(22):3000-4. (Pubitemid 37430103)
35. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(3-4):222-31. (Pubitemid 351481853)
36. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9(3):299-314.
37. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437-46. (Pubitemid 32730790)
38. Kuglemas M, Hill D, Vivian B, Marsano L, McClain C. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-9. (Pubitemid 36919862)
39. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-11. (Pubitemid 32141844)
40. Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol Genomics. 2007;31(2):216-27. (Pubitemid 350014399)
41. Feingold KR, Soued M, Serio MK, Adi S, Moser AH, Grunfeld C. The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis. Metabolism. 1990;39(6):623-32. (Pubitemid 20184534)
42. Grunfeld C, Feingold KR. Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense. Proc Soc Exp Biol Med. 1992;200:224-7.
43. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007;28(4):365-86. (Pubitemid 46984825)
44. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut. 2006;55(3):415-24. (Pubitemid 43268283)
45. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-37. (Pubitemid 28053135)
46. Sehgal PB, Greininger G, Tosato G. Regulation of the acute phase and immune responses: interleukin 6. Ann NY Acad Sci. 1989;557:1-583.
47. Brass EP, Vetter WH. Interleukin-6, but not tumour necrosis factor-alpha, increases lipogenesis in rat hepatocyte primary cultures. Biochem J. 1994;301(Pt 1):193-7. (Pubitemid 24214700)
48. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301. (Pubitemid 36724371)
49. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53(4):1060-7. (Pubitemid 38436619)
50. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S53-5. (Pubitemid 38019190)
51. Senn JJ, Klover PJ, Nowak IA, Mooney RA. IL-6 induces insulin resistance in hepatocytes. Diabetes. 2002;51:3391-9. (Pubitemid 35403441)
52. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
53. Skapenko A, Niedobitek GU, Kalden JR, Lipsky PE, Schulze-Koops H. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol. 2004;172(10):6427-34. (Pubitemid 38621252)
54. Cintra DE, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 2008;48(4):628-37.
55. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72.